F2G
Study at a Glance
Estimated Time Commitment
To be discussedEligibility
Individuals with Refractory Invasive Fungal DiseaseDiagnosis Required
Confirmed diagnosis of Refractory Invasive Fungal DiseaseDiseases Being Studied
Refractory Invasive Fungal DiseaseSponsor: F2G
Coordinating Center/CRO: Quintiles
Primary Objective: Describe the Data Review Committee (DRC)-adjudicated efficacy of F901318 as treatment for infections due to resistant fungi in patients lacking suitable alternative treatment options.
Study drugs: open label olorofim
Sample size: estimated at 200
Current enrollment at our site: 3